Omnimmune Holdings, Inc. is engaged in the provision of cancer therapeutic, diagnostic and prognostic technologies. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2007-12-19. The firm is the holding company of Omnimmune Corp. Omnimmune has acquired licensed rights to diagnostic and platform monoclonal antibody technologies. Omnimmune’s hCGß and related technologies, which are protected through an expanding intellectual property portfolio, have been developed at institutions including Columbia University of New York, New York (Columbia), The Allegheny-Singer Research Institute of the West Penn Allegheny Health System, Pittsburgh, Pennsylvania (Allegheny) and The Institute Gustave Roussy, Paris, France (IGR).
Follow-Up Questions
Qui est le CEO de Omnimmune Holdings Inc ?
Travis McPhee est le Chief Executive Officer de Omnimmune Holdings Inc, il a rejoint l'entreprise depuis 2007.
Quelle est la performance du prix de l'action OMMH ?
Le prix actuel de OMMH est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Omnimmune Holdings Inc ?
Omnimmune Holdings Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Omnimmune Holdings Inc ?
La capitalisation boursière actuelle de Omnimmune Holdings Inc est de $0
